膝下冠状动脉药物洗脱支架血运重建改善严重肢体缺血伴组织缺损患者的临床结局
这项多中心回顾性研究纳入32例严重肢体缺血(CLI)伴组织缺损患者共40次膝下动脉血运重建,使用冠状动脉药物洗脱支架(DES)。平均随访19.3个月,免于大截肢率88.6%,一年一期通畅率90.3%,踝肱指数和WIfI各组分均显著改善,WIfI大截肢风险评分从3.58降至2.04。
要点
- 冠状动脉DES用于膝下病变可获良好一期通畅率和保肢率
- 血运重建后ABI及WIfI各组分均显著改善
- WIfI评分可用于客观评估血运重建后结局
核心结论
- 冠状动脉DES在合适选择的CLI伴组织缺损患者的多平面血运重建中显示良好的一期通畅率和保肢率。
- WIfI评分不仅可预测大截肢和血运重建获益,还可作为多组分工具客观评估血运重建后结局。
研究设计与样本
- 回顾性研究,纳入32例CLI患者的40次序贯膝下动脉血运重建手术。
- 平均随访19.3个月(四分位距7-27.1个月)。
主要发现
- 免于大截肢率为88.6%,一年一期通畅率为90.3%。
- 踝肱指数从0.57±0.26增至0.97±0.26(P=0.03)。
- WIfI评分各组分显著改善:W从1.9降至1.1(P=0.03),I从2.0降至0.6(P=0.001),fI从1.5降至0.8(P=0.01)。
- WIfI大截肢风险评分从3.58±0.75(高风险)降至2.04±1.31(低风险;P<0.001)。
- 一年生存率为90.6%。
关键数值与推荐
- 冠状动脉DES用于尺寸合适的膝下病变。
- WIfI评分用于评估血运重建前后结局。
临床怎么用
- 对合适选择的CLI伴组织缺损患者,可考虑使用冠状动脉DES行膝下血运重建。
- 应用WIfI评分客观评估血运重建前后组织缺损、缺血和足部感染的变化。
局限性
- 回顾性研究设计。
- 样本量小(32例患者、40次手术)。
- 缺乏FDA批准的膝下适应证和专用支架技术。
- 超过1年的随访数据 scarce。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Critical limb ischemia (CLI) involving infrapopliteal arterial atherosclerosis and tissue loss remains a formidable clinical scenario with significant morbidity and mortality. Despite level IA evidence, tibial revascularization with coronary drug-eluting stents (DES) remains a seldom-used technique in the United States due, in part, to lack of a Food and Drug Administration-approved indication and dedicated stent technology for infrapopliteal application. Furthermore, follow-up data beyond 1 year remain scarce, and further evidence for improvement in clinical outcomes using this technique is needed. Herein, we present our multi-institutional experience with endovascular revascularization of patients with CLI and tissue loss using coronary DES for infrapopliteal lesions of appropriate dimensions and the Wound, Ischemia, and foot Infection (WIfI) score as supportive evidence for improvement in clinical outcomes. METHODS: In this retrospective study, 40 sequential tibial revascularization procedures performed in 32 patients with CLI were reviewed. Outcomes including changes in WIfI scores, patency rates, freedom from major amputation, target lesion recurrence, and all-cause mortality were analyzed. Average follow-up duration was 19.3 months (interquartile range: 7-27.1 months). RESULTS: Freedom from major amputation was 88.6%. One-year primary patency was 90.3%. Mean ankle-brachial indices increased after revascularization (0.57 ± 0.26 to 0.97 ± 0.26; P = 0.03). All components of the WIfI score significantly improved after revascularization (W: 1.9 to 1.1, P = 0.03; I: 2.0 to 0.6, P = 0.001; and fI: 1.5 to 0.8, P = 0.01). WIfI risk of major amputation score before revascularization was 3.58 ± 0.75 (high risk), which was reduced to 2.04 ± 1.31 (low risk; P < 0.001). One-year survival rate was 90.6%. CONCLUSIONS: Coronary DES continue to demonstrate promising primary patency and limb salvage rates in appropriately selected patients undergoing multilevel endovascular revascularization for CLI and tissue loss. In addition to its value as a predictor for major amputation and revascularization benefit, the WIfI score can also serve as a multicomponent tool for objective assessment of outcomes after revascularization.
引用
- Huntress LA, Fereydooni A, Dardik A, et al. Endovascular Revascularization Incorporating Infrapopliteal Coronary Drug-Eluting Stents Improves Clinical Outcomes in Patients with Critical Limb Ischemia and Tissue Loss. Ann Vasc Surg. 2019. PMID: 31563654. doi:10.1016/j.avsg.2019.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。